| 摘要 |
The present invention relates to a composition for preventing, diagnosing, or treating diseases related to skeletal muscle relaxation disorder, wherein STIM1 is combined with SERCA1a to promote an activity of SERCA1a, so that skeletal muscle relaxation is promoted. Accordingly, skeletal muscle relaxation disorder and diseases having symptoms of constriction, such as the Brodie′s syndrome, paramyotonia, muscular dystrophy, and cerebral paralysis, can be prevented, diagnosed, or treated. The mRNA or protein level of STIM1 is measured to diagnose diseases having skeletal muscle relaxation disorder. |
